175
Participants
Start Date
November 30, 2010
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
AFQ056
AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
Placebo
Placebo medication identical in appearance to active medication was provided
Novartis Investigative Site, Ryde
Novartis Investigative Site, Waratah
Novartis Investigative Site, Glostrup Municipality
Novartis Investigative Site, Caulfield
Novartis Investigative Site, Zurich
Novartis Investigative Site, Staten Island
Novartis Investigative Site, Berlin
Novartis Investigative Site, Genova
Novartis Investigative Site, Media
Novartis Investigative Site, Málaga
Novartis Investigative Site, Greenwood
Novartis Investigative Site, Decatur
Novartis Investigative Site, Nashville
Novartis Investigative Site, Indianapolis
Novartis Investigative Site, Mainz
Novartis Investigative Site, Chicago
Novartis Investigative Site, Bron
Novartis Investigative Site, Tübingen
Novartis Investigative Site, Paris
Novartis Investigative Site, Houston
Novartis Investigative Site, Phoenix
Novartis Investigative Site, Sacramento
Novartis Investigative Site, Würzburg
Novartis Investigative Site, Boston
Novartis Investigative Site, Omaha
Novartis Investigative Site, Brampton
Novartis Investigative Site, Sherbrooke
Novartis Investigative Site, Roma
Novartis Investigative Site, Sant Cugat del Vallès
Novartis Investigative Site, Lausanne
Novartis Investigative Site, Edinburgh
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY